2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-152120
    (±)-Aiphanol 578020-29-8
    (±)-Aiphanol is a newly discovered stilbenolignan analog. (±)-Aiphanol exhibits significant anti-inflammatory activity, acting through inhibition of COX-1 and COX-2. The inhibitory effect on COX-1 (IC50 = 1.9 μM) is particularly strong, while the effect on COX-2 (IC50= 9.9 μM) is relatively weak.(±)-Aiphanol effectively inhibits VEGFR2 (IC50=0.92 μM). (±)-Aiphanol blocks angiogenesis and promotes apoptosis through inhibition of VEGFR2 and COX2 activity. (±)-Aiphanol is orally active.
    (±)-Aiphanol
  • HY-152137
    Antituberculosis agent-7 2874263-73-5
    Antituberculosis agent-7, an oxetanyl-quinoline derivative, has shown good antibacterial activity against P. mirabilis with a MIC of 31.25 μM. Antituberculosis agent-7 shows good antifungal activity against A. niger with a MIC of 62.5 μM. Antituberculosis agent-7 shows excellent antimycobacterial activity with MIC 3.41 μM for M. tuberculosis H37Rv.
    Antituberculosis agent-7
  • HY-152139
    Antibacterial agent 129 2874263-66-6
    Antibacterial agent 129, an oxetanyl-quinoline derivative, has shown good antibacterial activity against P. mirabilis and B. subtilis with MICs of 31.25 μM and 31.5 μM and . Antibacterial agent 129 shows good antifungal activity against A. niger with a MIC of 31.25 μM. Antibacterial agent 129 shows excellent antimycobacterial activity with MIC 57.73 μM for M. tuberculosis H37Rv.
    Antibacterial agent 129
  • HY-152200
    HIV-1 inhibitor-53 2883496-10-2
    HIV-1 inhibitor-53 is a dual HIV-1 protease and reverse transcriptase inhibitor. HIV-1 inhibitor-53 inhibits HIV-1 protease (PR) and reverse transcriptase (RT) activity with IC50 values of 1.93 nM and 2.35 μM, respectively. HIV-1 inhibitor-53 can be used for the research of acquired immune deficiency syndrome (AIDS).
    HIV-1 inhibitor-53
  • HY-152212
    BTK-IN-19 1374240-01-3
    BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM.
    BTK-IN-19
  • HY-152213
    BET-IN-13 2506823-08-9
    BET-IN-13 is a potent BET inhibitor with an IC50 value of 1.6 nM. BET-IN-13 reduces LPS-induced TNF-α, IL-1β, IL-6, and NOS2 mRNA expression levels. BET-IN-13 shows anti-inflammatory activity. BET-IN-13 has the potential for the research of acute liver injury.
    BET-IN-13
  • HY-152251
    CB2R/FAAH modulator-1 928892-60-8
    CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with Kis of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production.
    CB2R/FAAH modulator-1
  • HY-152253
    CB2R/FAAH modulator-2 2876918-68-0
    CB2R/FAAH modulator-2 (compound 26) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The Ki values for CB2R/FAAH modulator-2 are 10.8 and 152.9 nM for CB2R and CB1R, respectively, and the IC50 value for FAAH is 6.2 μM. CB2R/FAAH modulator-2 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection.
    CB2R/FAAH modulator-2
  • HY-15234S
    Fluticasone furoate-d3
    Fluticasone furoate-d3 is deuterium labeled Fluticasone furoate. Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated corticosteroid with a Kd of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure. Fluticasone furoate has the potential for allergic rhinitis treatment[1][2].
    Fluticasone furoate-d3
  • HY-152535
    ATV041 2935937-67-8
    ATV041 is an orally active Ibuprofen (HY-78131) and nucleotide analogue. ATV041 improves oral pharmacokinetic (PK) profile and tissue distribution with anti-mouse hepatitis virus (MHV) activity. ATV041 reduces viral load, tissue damage and virus-induced inflammation in a dose-dependent manner.
    ATV041
  • HY-152576
    CB2R agonist 1 1817633-49-0
    CB2R agonist 1 is a selective ligand of cannabinoid receptor subtype 2 (CB2R) with an EC50 value of 0.56 µM. CB2R agonist 1 has high affinity and excellent selectivity for human CB2R and CB1R respectively. CB2R agonist 1 regulates the production of pro-inflammatory cytokines and anti-inflammatory cytokines and play an immunomodulatory role.
    CB2R agonist 1
  • HY-152925
    FA-15 4932-15-4
    FA-15 is an phenolic antioxidant. FA-15 has effect on stabilization of reactive fuels.
    FA-15
  • HY-152954
    DRAK1/2-IN-1 1629227-34-4
    DRAK1/2-IN-1 (compound 10e) is an active dual DRAK1 and DRAK2 inhibitor with Kd values of 1 μM and 6 μM, respectively.
    DRAK1/2-IN-1
  • HY-153002
    p38α inhibitor 3 260428-69-1 99.82%
    p38α inhibitor 3 (Comp G7) is a p38α inhibitor that blocks the effectiveness of myoblast differentiation.
    p38α inhibitor 3
  • HY-153070
    TLR7 agonist 5 2380231-67-2
    TLR7 agonist 5 (compound IIb-11) is an TLR7 agonist with an EC50 value of ~4 nM.
    TLR7 agonist 5
  • HY-153072
    TLR7 agonist 7 2380231-77-4
    TLR7 agonist 7 (compound IIb-26) is an TLR7 agonist with an EC50 value of ~4 nM.
    TLR7 agonist 7
  • HY-153073
    TLR7 agonist 8 2380231-81-0
    TLR7 agonist 8 (compound IIb-34) is an TLR7 agonist with an EC50 value of ~4 nM.
    TLR7 agonist 8
  • HY-153085
    CD19 CAR circRNA
    CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR circRNA
  • HY-153103
    LRRK2/NUAK1/TYK2-IN-1 2629192-96-5
    LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1, with IC50 values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research.
    LRRK2/NUAK1/TYK2-IN-1
  • HY-15315S
    Baricitinib-d5 1564241-79-7
    Baricitinib-d5 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.
    Baricitinib-d5
Cat. No. Product Name / Synonyms Application Reactivity